Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 5/20 | 0.53 |
| ▸ | CSF1R | P07333 | 11/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17457390 | 0.99 | BRD4 (0.54) | BRD4CSF1RALDH1A1NPSR1CASP1 | |
| SCHEMBL17457305 | 0.92 | PDGFRB (0.48) | BRD4CSF1RALDH1A1NPSR1CASP1 | |
| SCHEMBL17457417 | 0.92 | HSD17B10 (0.56) | BRD4CSF1RALDH1A1NPSR1CASP1 | |
| SCHEMBL17457303 | 0.84 | CSF1R (0.47) | BRD4CSF1RHTR2AHTR2C | |
| SCHEMBL4848995 | 0.82 | CSF1R (0.66) | CSF1RALDH1A1NPSR1CASP1HSD17B10 | |
| SCHEMBL4844116 | 0.82 | CSF1R (0.66) | CSF1RALDH1A1NPSR1CASP1HSD17B10 | |
| SCHEMBL17457300 | 0.78 | NPSR1 (0.44) | CSF1RALDH1A1NPSR1CASP1HSD17B10 | |
| SCHEMBL17457319 | 0.77 | NPSR1 (0.44) | CSF1RALDH1A1NPSR1CASP1HSD17B10 | |
| SCHEMBL16111646 | 0.76 | CSF1R (0.70) | BRD4CSF1R | |
| SCHEMBL4844211 | 0.76 | CSF1R (0.62) | CSF1RALDH1A1NPSR1CASP1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2968360-B1 | QUINOLINONE DERIVATIVES FOR THE INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS | CONVERGENE LLC (US) | 2021-01-20 | — | — | EP | disclosed |
| US-10717739-B2 | Methods and compositions for inhibition of bromodomain-containing proteins | CONVERGENE LLC (US) | 2020-07-21 | — | — | US | disclosed |
| US-10717739-B2 | Methods and compositions for inhibition of bromodomain-containing proteins | CONVERGENE LLC (US) | 2020-07-21 | — | — | US | disclosed |
| US-20190345162-A1 | Methods and Compositions for Inhibition of Bromodomain-Containing Proteins | CONVERGENE LLC | 2019-11-14 | — | — | US | disclosed |
| US-20190345162-A1 | Methods and Compositions for Inhibition of Bromodomain-Containing Proteins | CONVERGENE LLC | 2019-11-14 | — | — | US | disclosed |
| US-10266536-B2 | Methods and compositions for inhibition of bromodomain-containing proteins | CONVERGENE LLC (US) | 2019-04-23 | — | — | US | disclosed |
| US-10266536-B2 | Methods and compositions for inhibition of bromodomain-containing proteins | CONVERGENE LLC (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180134715-A1 | Methods and Compositions for Inhibition of Bromodomain-Containing Proteins | CONVERGENE LLC | 2018-05-17 | — | — | US | disclosed |
| US-20180134715-A1 | Methods and Compositions for Inhibition of Bromodomain-Containing Proteins | CONVERGENE LLC | 2018-05-17 | — | — | US | disclosed |
| US-20180134715-A1 | Methods and Compositions for Inhibition of Bromodomain-Containing Proteins | CONVERGENE LLC | 2018-05-17 | — | — | US | disclosed |
| US-9695179-B2 | Methods and compositions for inhibition of bromodomain-containing proteins | CONVERGENE LLC (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695179-B2 | Methods and compositions for inhibition of bromodomain-containing proteins | CONVERGENE LLC (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695179-B2 | Methods and compositions for inhibition of bromodomain-containing proteins | CONVERGENE LLC (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160024096-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS | CONVERGENE LLC (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160024096-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS | CONVERGENE LLC (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160024096-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS | CONVERGENE LLC (US) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10717739-B2 | Methods and compositions for inhibition of bromodomain-containing proteins | BRPF3, BRD3, BRDT | BRD4 4/4885CSF1R 3174/4885ALDH1A1 4430/4885 |
| US-20190345162-A1 | Methods and Compositions for Inhibition of Bromodomain-Containing Proteins | BRPF3, BRD3, BRDT | BRD4 4/4885CSF1R 3174/4885ALDH1A1 4430/4885 |
| US-10266536-B2 | Methods and compositions for inhibition of bromodomain-containing proteins | BRPF3, BRD3, BRDT | BRD4 4/4885CSF1R 3174/4885ALDH1A1 4430/4885 |
| US-20180134715-A1 | Methods and Compositions for Inhibition of Bromodomain-Containing Proteins | BRPF3, BRD3, BRDT | BRD4 4/4885CSF1R 3174/4885ALDH1A1 4430/4885 |
| US-20160024096-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, BRD3, BRDT | BRD4 4/4885CSF1R 3174/4885ALDH1A1 4430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.